KRAS and neoplasm: In a preclinical study, the combination of nintedanib (a triple angiokinase inhibitor of VEGFRs, PDGFRs, and FGFRs) and afatinib (an irreversible pan-ErbB inhibitor of EGFR, ErbB2, ErbB3, and ErbB4) potently inhibited tumor growth in HT-29 xenograft model regardless of the Kirsten rat sarcoma viral oncogene homolog (KRAS) status [15].